[Retrospective analysis concerning AFP-producing gastric cancer].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Gan To Kagaku Ryohosha Country of Publication: Japan NLM ID: 7810034 Publication Model: Print Cited Medium: Print ISSN: 0385-0684 (Print) Linking ISSN: 03850684 NLM ISO Abbreviation: Gan To Kagaku Ryoho Subsets: MEDLINE
    • Publication Information:
      Publication: Tokyo : Gan To Kagaku Ryohosha
      Original Publication: Tōkyō, Gan to Kagaku Ryōhōsha [1974?]-
    • Subject Terms:
      Stomach Neoplasms/*metabolism ; alpha-Fetoproteins/*biosynthesis; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Stomach Neoplasms/chemistry ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/therapy ; alpha-Fetoproteins/analysis
    • Abstract:
      The α-fetoprotein(AFP)-producing gastric cancer is a group of gastric cancers with poor prognosis because of its rapid growth and aggressive metastatic character. We examined AFP-producing gastric cancer in our department from 2008 to 2010. Of 12 patients studied, the median of the AFP level was 16, 038(96. 1-167, 360)ng/mL. All patients had liver metastasis. Four patients were ECOG performance status(PS)3, and were unable to receive chemotherapy. Eight patients received chemotherapy. Two cases who received cisplatin+paclitaxel(CDDP+PTX)therapy showed partial response(PR). Median survival time was 5. 6 months. Compared to AFP non-producing gastric cancer, this disease is definitely considered to have a poorer prognosis. The clinical effect and survival time seemed to have a relative correlation. PR and SD groups tend to have longer survival. Those with a decline of serum LDH levels at the first three weeks after chemotherapy have a strong tendency to be PR and SD(p=0. 11). Changing the serum LDH level may enable us to estimate the clinical effect while still in the early stages of chemotherapy.
    • Accession Number:
      0 (alpha-Fetoproteins)
    • Publication Date:
      Date Created: 20130216 Date Completed: 20130312 Latest Revision: 20130215
    • Publication Date:
      20240829
    • Accession Number:
      23411954